Search Results for: "Clinic Roundup"
-
Clinic Roundup
The 207-patient study is designed to demonstrate that the rate of cocaine-dependent subjects treated with the GABA analogue who abstain from cocaine use in the last two weeks of the treatment phase will be higher than patients treated with placeboBioWorld Today | Thursday, September 27, 2012 -
Clinic Roundup
Data from the 20-patient study showed that all patients had a decrease in giant cells of 90 percent or greater, an indication of a reduction of tumor burdenBioWorld Today | Monday, September 24, 2012 -
Clinic Roundup
Generex Biotechnology Corp., of Worcester, Mass., reported early results from a Phase II study of its AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer, which showed an overall reduction of 42 percent in the risk of relapse in all patients in the study who received the vaccine, and a 66 percent reduction in the risk of relapse for patients with low expression of the HER2 oncoprotein who were classified as having triple-negative breast cancerBioWorld Today | Friday, September 14, 2012 -
Clinic Roundup
The open-label, 1 , 100-patient study will evaluate the potential survival benefit of combining custirsen with docetaxel in patients who have progressed after first-line treatmentBioWorld Today | Wednesday, July 11, 2012 -
Clinic Roundup
The 420-patient study is designed to determine the efficacy of the selective adenosine 2A receptor inhibitor in reducing the mean number of hours per day patients spend in the "off" stateBioWorld Today | Friday, July 6, 2012 -
Clinic Roundup
Patients in the study were given a single infusion of either Prochymal or placebo through a standard intravenous line within seven days of an acute heart attackBioWorld Today | Tuesday, July 3, 2012 -
Clinic Roundup
The 506-patient study is being conducted under a special protocol assessment from the FDABioWorld Today | Thursday, June 21, 2012 -
Clinic Roundup
All patients in the study will also be on the current standard of care to control hypertension, hyperglycemia and dyslipidemia, the company saidBioWorld Today | Wednesday, June 20, 2012 -
Clinic Roundup
Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said it enrolled the first patient for Study NX03-0040, a Phase II study testing NX-1207 in low risk localized prostate cancerBioWorld Today | Wednesday, June 13, 2012 -
Pharma: Clinic Roundup
While the 83-patient study was not powered for efficacy, the data demonstrated that thrombolysis (greater than or equal to 50 percent) occurred in 79 percent of subjects receiving 125 mg to 175 mg of plasmin, compared to 50 percent who received 25 mg to 100 mgBioWorld Today | Tuesday, June 12, 2012 -
Clinic Roundup
Data from the 32-patient study, which measured central subfield retinal thickness as the primary endpoint, showed that higher doses of Optina were more effective for patients with higher BMI and lower doses were more effective for patients with lower BMIBioWorld Today | Tuesday, June 12, 2012 -
Clinic Roundup
Initial indications from the 15-patient study indicated that Xerecept can reduce or eliminate the need for Decadron use and provide significant quality of life improvementsBioWorld Today | Wednesday, May 23, 2012 -
Clinic Roundup
The 1,000 patient study is being conducted under a special protocol assessment and is measuring overall survival as the primary endpointBioWorld Today | Monday, May 21, 2012 -
Clinic Roundup
Primary endpoint data for the 127-patient study showed that the group receiving naloxone had a highly significant (p < 0.001) reduction in their time spent binge eating...Uluru Inc., of Addison, Texas, said it expanded its 60-patient study of wound treatment technology Altrazeal to include 500 patients to support the launch of the drug in Australia and New ZealandBioWorld Today | Friday, May 4, 2012 -
Clinic Roundup
The 176-patient study is designed to measure improvement in forced expiratory volume in one second as the primary endpointBioWorld Today | Friday, March 23, 2012 -
Clinic Roundup
Patients in the study will receive ofatumumab plus chemotherapy or Rituxan (rituximab, Biogen Idec Inc. and Roche AG) plus chemotherapyBioWorld Today | Tuesday, March 20, 2012 -
Clinic Roundup
The 164-patient study is testing oral Trimesta or placebo in addition to Copaxone (glatiramer acetate, Teva Pharmaceuticals Inc.) in women between 18 and 50 who recently have been diagnosed with relapsing-remitting MSBioWorld Today | Thursday, March 15, 2012 -
Clinic Roundup
The 228-patient study is designed to assess the drug's efficacy, safety and tolerabilityBioWorld Today | Tuesday, March 13, 2012 -
Clinic Roundup
Results from the 258-patient study also showed that those treated with Solabegron reported a significant reduction in the frequency of urination and a marked and significant increase in the volume of urine voided, both compared to placeboBioWorld Today | Friday, March 2, 2012 -
Clinic Roundup
Oragenics Inc., of Tampa, Fla., said a 32-patient study testing its weight-loss agent LPT3-04 over a 12-week period showed a statistically and clinically significant reduction in body weight in healthy, overweight and mildly obese adult volunteersBioWorld Today | Wednesday, February 15, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.